10-Q: Kaya Holdings Reports Q3 2024 Results, Navigates Shift to Psychedelic Therapies

Kaya Holdings reports a net loss for Q3 2024, primarily due to changes in derivative liabilities, as it transitions from cannabis operations to focus on its new psilocybin treatment center.

Summary

• Kaya Holdings, Inc. reported a net loss of $2,495,327 for the three months ended September 30, 2024, compared to a net income of $2,095,742 for the same period in 2023.
• The company's revenue decreased significantly to $3,000 in Q3 2024 from $59,011 in Q3 2023, primarily due to the closure of its Oregon cannabis retail operations.
• Operating expenses remained high, with professional fees at $813,829 and general and administrative expenses at $291,444 for the quarter.
• The company experienced a significant loss of $1,084,865 due to changes in derivative liabilities, which impacted the overall financial results.
• For the nine months ended September 30, 2024, the company's net loss was $3,139,691, compared to a net income of $1,368,016 for the same period in 2023.
• The company's cash position increased to $64,794 as of September 30, 2024, but it has a working capital deficiency of $8,982,011.
• Kaya Holdings is transitioning its focus to its newly licensed psilocybin treatment center, The Sacred Mushroom, which opened in July 2024.
• The company issued 19,400,000 restricted shares to officers, directors, consultants, and for the lease of The Sacred Mushroom.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in opening its psilocybin treatment center, the financial results are poor, with significant losses and a substantial working capital deficiency. The company's future is highly dependent on its ability to raise capital and successfully transition to the psychedelic market.

Positives

• The company successfully obtained a license and opened its psilocybin treatment center, The Sacred Mushroom, in July 2024.
• Kaya Holdings is positioned as the first US public company to own and operate a licensed psychedelic treatment facility.
• The company has a plan to leverage its experience in the cannabis industry to expand into the emerging psychedelic therapeutics market.
• The company's cash position increased to $64,794 during the quarter.

Negatives

• The company experienced a significant net loss of $2,495,327 in Q3 2024, a sharp decline from the net income of $2,095,742 in Q3 2023.
• Revenue decreased dramatically to $3,000 in Q3 2024, down from $59,011 in Q3 2023.
• The company has a substantial working capital deficiency of $8,982,011.
• The company recorded a loss of $1,084,865 due to changes in derivative liabilities.
• The company's disclosure controls and procedures were deemed not effective as of September 30, 2024.
• The company's internal control over financial reporting was also deemed not effective as of September 30, 2024.

Risks

• The company's ability to continue as a going concern is in substantial doubt due to its working capital deficiency and dependence on raising capital.
• The company faces significant competition in both the cannabis and psychedelic medicine sectors.
• The company's operations are subject to evolving regulations and laws, which could expose it to substantial liability.
• The company's financial results are highly dependent on the success of its new psilocybin treatment center.
• The company's internal controls over financial reporting are not effective, which could lead to misstatements in financial reports.
• The company is subject to risks associated with the legal status of psilocybin under federal law.

Future Outlook

Management believes that further proceeds from financing transactions, combined with existing and anticipated revenues, will alleviate the company's financial difficulties and allow it to meet its working capital needs for a period of between twelve and eighteen months. However, there is no assurance that further funding will be achieved or that it will be sufficient.

Management Comments

• The company is focusing on wellness and mental health through operations in psychedelic treatment clinics, medical and recreational cannabis, and CBD products.
• KAYS plans to operate The Sacred Mushroom as part of its Fifth Dimension Therapeutics, Inc. subsidiary (FDT), which also plans to work cooperatively with select pharmaceutical companies to maximize the curative and therapeutic potential of psilocybin.
• The psilocybin opportunity is a logical extension for Kaya Holdings, and the company anticipates being able to respond to market demand rapidly, upon licensing.
• The company believes that its facility offers a superior setting, broader activity and treatment options with pricing at or near the lower range, thereby enabling it to deliver a superior treatment experience at a much lower price than the competition, while still achieving profitability.

Industry Context

The company is navigating a shift from the cannabis industry to the emerging psychedelic therapeutics market, which is gaining traction with the legalization of psilocybin in Oregon and other regions. The company is positioning itself to be a leader in this new market, leveraging its experience in the cannabis industry and its understanding of regulatory requirements.

Comparison to Industry Standards

• The company's revenue decline in the cannabis sector is consistent with a strategic shift away from that market, which is a common trend for companies pivoting to the psychedelic space.
• The company's move to open a psilocybin treatment center aligns with the growing interest in psychedelic therapies for mental health, similar to companies like Compass Pathways, ATAI Life Sciences, and Cybin, which are developing synthetic versions of psilocybin.
• The company's focus on a physical treatment center contrasts with some companies that are primarily focused on drug development, suggesting a different approach to the market.
• The company's reported losses are not uncommon for companies in the early stages of the psychedelic market, which often require significant investment in research, development, and infrastructure.
• The company's pricing strategy for psilocybin treatments, aiming for the lower end of the market, is a competitive approach that could attract a broader customer base.

Legal Proceedings

• The company settled a lawsuit with P3 Distributing LLC on October 17, 2024, requiring monthly payments of $300 for 18 months with a balloon payment of $11,779.20 at the end.

Related Party Transactions

• The company had $754,557 in accounts payable and accrued expenses to related parties as of September 30, 2024.
• The company issued 1,000,000 shares of common stock to FDT Oregon 1 LLC owners, who are also related parties, to acquire the remaining 51% equity interest of FDT Oregon 1 LLC after January 1, 2025.

Stakeholder Impact

• Shareholders are impacted by the company's significant net loss and working capital deficiency.
• Employees are impacted by the company's transition and potential future growth.
• Customers of The Sacred Mushroom will be impacted by the company's new psilocybin treatment services.
• Creditors are impacted by the company's debt and financial challenges.

Next Steps

• The company plans to continue developing its Oregon psilocybin business.
• The company plans to develop its international projects in Greece.
• The company will seek additional financing to fund its growth plan.

Key Dates

Keywords

psilocybin, psychedelic therapy, cannabis, mental health, treatment center, Kaya Holdings, financial results, derivative liabilities, working capital, The Sacred Mushroom